The CEO Roundtable on Cancer brings together major pharmaceutical companies, healthcare organizations, and corporate leaders all committed to eliminating cancer.
These leading companies and institutions have joined the CEO Roundtable on Cancer in its mission to make measurable progress against cancer.
A global research-based biopharmaceutical company with a robust oncology portfolio spanning hematologic malignancies and solid tumors, including therapies for chronic lymphocytic leukemia, acute myeloid leukemia, and multiple myeloma.
A life sciences industry partner providing end-to-end contact centers, technical support, and customer-centric solutions for pharma and healthcare clients. Founded in 1979 and operating in 122 countries, Alphanumeric has been a CEO Cancer Gold Standard™ employer since 2022. CEO Randy Trice, an active member of the CEO Roundtable on Cancer, was instrumental in achieving the Gold Standard Accreditation and has led Alphanumeric through significant growth in market share and profitability. He also serves as a Wake County Boys & Girls Club Board Member.
A leading global biotechnology company with a significant oncology portfolio, including treatments for blood cancers and solid tumors. Amgen's Chairman and CEO Robert Bradway served as CEORT chairman from 2015 to 2022.
A Japanese multinational pharmaceutical company with a growing oncology focus, including targeted therapies and antibody-drug conjugates for advanced cancers.
A global biopharmaceutical company with one of the industry's largest oncology pipelines, spanning lung, breast, ovarian, and blood cancers.
A global business management and consulting firm that supports CEORT's "Going for Gold" health equity initiative, advancing cancer awareness and prevention at HBCUs and minority-serving institutions.
A German multinational life sciences company with a pharmaceuticals division focused on oncology, including targeted cancer therapies and radiopharmaceuticals.
A global, family-owned pharmaceutical company with an oncology research portfolio focused on innovative cancer treatments, including lung cancer therapies.
A global medical device company that manufactures interventional oncology products used in minimally invasive cancer treatments, including tumor ablation and embolization devices.
A global strategic branding consultancy specializing in pharmaceutical, biotech, and healthcare brand name development, including naming for oncology drugs.
A major global pharmaceutical company and leader in immuno-oncology, known for breakthrough cancer immunotherapies including checkpoint inhibitors for melanoma, lung cancer, and other malignancies.
A Japanese multinational pharmaceutical company with a rapidly growing oncology portfolio, particularly known for pioneering antibody-drug conjugate technology for cancer treatment.
A major global pharmaceutical company with significant oncology investments, including therapies for breast cancer, lung cancer, and other solid tumors.
The U.S. biopharmaceutical business of Merck KGaA, focused on oncology and immuno-oncology therapies including treatments for advanced cancers.
A leading independent investment banking advisory firm that provides strategic advisory services to healthcare and life sciences companies in M&A and capital markets.
A molecular diagnostics company and pioneer in comprehensive genomic profiling for cancer, helping oncologists match patients with targeted therapies and clinical trials.
A global biopharma company with a significant oncology portfolio, including treatments for blood cancers and solid tumors, and investments in immuno-oncology and cell therapy.
A venture capital firm based in Durham, NC, focused on early-stage investments in life sciences, including oncology therapeutics and diagnostics companies.
A Swiss pharmaceutical group focused on cancer supportive care, developing treatments that improve quality of life for cancer patients, particularly managing chemotherapy-related side effects.
A leading global provider of clinical research services, healthcare analytics, and technology solutions that support oncology drug development and real-world evidence generation.
The pharmaceutical arm of Johnson & Johnson with a major oncology portfolio spanning treatments for multiple myeloma, prostate cancer, lung cancer, and bladder cancer.
A clinical trial technology company providing decentralized and hybrid trial platforms deployed across nearly 400 trials in 70 countries, helping accelerate oncology and other clinical research.
An Italian pharmaceutical and diagnostics company with a growing oncology presence, developing targeted cancer therapies through its subsidiary Stemline Therapeutics.
A major global pharmaceutical company and leader in immuno-oncology through its blockbuster PD-1 inhibitor Keytruda, one of the most widely used cancer immunotherapies worldwide.
A German science and technology company with a healthcare division that develops oncology treatments, including targeted therapies and immuno-oncology agents. Operates as EMD Serono in the U.S.
A global pharmaceutical leader with a major oncology franchise spanning targeted therapies, radioligand therapy, and CAR-T cell therapy, making it one of the largest oncology drug developers worldwide.
A UnitedHealth Group company providing data analytics, pharmacy care services, and population health management, including oncology care management programs and real-world data for cancer research.
An AI-driven patient empowerment platform that helps cancer patients navigate their care from diagnosis through treatment, providing personalized, evidence-based information including clinical trial matching.
A global pharmaceutical company with a substantial oncology portfolio, including treatments for breast cancer, prostate cancer, and blood cancers, and expanding into antibody-drug conjugates.
A medical imaging AI company deployed in 3,100+ hospitals across 90+ countries, using deep learning to improve early detection and diagnosis of conditions including lung cancer.
One of the world's largest oncology companies, pioneering targeted cancer therapies and diagnostics through its pharmaceutical division and subsidiary Genentech.
An independent, nonprofit research institute conducting research in cancer epidemiology, clinical trial methodology, and health equity to support evidence-based cancer prevention and treatment.
A global pharmaceutical company expanding its oncology portfolio through immunology-based cancer treatments and precision medicine approaches, including bispecific antibodies and antibody-drug conjugates.
A global leader in data analytics and AI, SAS provides the advanced analytical and visual analysis tools embedded directly within the Project Data Sphere platform, giving cancer researchers free access to run complex models and uncover insights without needing to export data or purchase expensive software.
A global biopharmaceutical company with a significant oncology franchise focused on hematologic malignancies, including multiple myeloma and lymphoma, as well as lung and gastrointestinal cancers.
One of the world's foremost academic cancer centers, consistently ranked #1 for cancer care in the U.S., conducting pioneering research in cancer treatment, prevention, and education.
The CEO Roundtable on Cancer welcomes new member organizations that share our commitment to eliminating cancer. Membership provides access to a unique coalition of leaders driving real change in cancer prevention, treatment, and research.
Join a coalition of the world's most influential organizations in the fight against cancer.